4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow beta-lapachone: new trials by email Literature Review of beta-lapachone trials Research Report on beta-lapachone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study for Patients Previously Treated With ARQ 501 ARQ 501 - Cancer | Phase 1 / Phase 2 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 | 2006-12-01 | 2013-02-28 |
| A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck ARQ 501 - Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 2 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 60 | 2006-07-01 | 2009-04-28 |
| Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma ARQ 501 - Cancer | Phase 2 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 30 | 2006-02-01 | 2009-04-29 |
| ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer ARQ 501 in combination with gemcitabine - Pancreatic Cancer, Adenocarcinoma | Phase 2 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 66 | 2005-01-01 | 2009-04-29 |
Neoplasms (3) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
United States (4)